Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
59.30
-0.70 (-1.17%)
Sep 21, 2026, 1:32 PM EDT - Market open
Sol-Gel Technologies Employees
Sol-Gel Technologies had 28 employees as of December 31, 2025. The number of employees decreased by 6 or -17.65% compared to the previous year.
Employees
28
Change (1Y)
-6
Growth (1Y)
-17.65%
Revenue / Employee
$64,107
Profits / Employee
-$583,464
Market Cap
194.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | -6 | -17.65% |
| Dec 31, 2024 | 34 | -2 | -5.56% |
| Dec 31, 2023 | 36 | -19 | -34.55% |
| Dec 31, 2022 | 55 | 2 | 3.77% |
| Dec 31, 2021 | 53 | -12 | -18.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Nkarta | 106 |
| Alpha Cognition | 71 |
| Acumen Pharmaceuticals | 61 |
| PepGen | 57 |
| Surrozen | 44 |
| Satellos Bioscience | 21 |
SLGL News
- 4 days ago - Sol-Gel Technologies announces last patient visit in SGT-610 trial - TheFly
- 4 days ago - Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome - GlobeNewsWire
- 4 weeks ago - Sol-Gel Technologies Earnings release: Q2 2026 - Filings
- 4 weeks ago - Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Sol-Gel Technologies initiated with an Outperform at Mizuho - TheFly
- 3 months ago - Sol-Gel Technologies initiated with a Buy at TD Cowen - TheFly
- 3 months ago - Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year - TheFly
- 3 months ago - Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire